BR0109515A - Derivados da apomorfina e métodos para seu uso - Google Patents

Derivados da apomorfina e métodos para seu uso

Info

Publication number
BR0109515A
BR0109515A BR0109515-3A BR0109515A BR0109515A BR 0109515 A BR0109515 A BR 0109515A BR 0109515 A BR0109515 A BR 0109515A BR 0109515 A BR0109515 A BR 0109515A
Authority
BR
Brazil
Prior art keywords
apomorphine
methods
derivatives
derived compounds
apomorphine derivatives
Prior art date
Application number
BR0109515-3A
Other languages
English (en)
Inventor
Pramod K Gupta
Debra Sutkowski-Markham
Deborah Milkowski
Original Assignee
Tap Pharmaceutical Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceutical Prod Inc filed Critical Tap Pharmaceutical Prod Inc
Publication of BR0109515A publication Critical patent/BR0109515A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

"DERIVADOS DA APOMORFINA E MéTODOS PARA SEU USO". Compostos derivados da apomorfina; composições farmaceuticamente ativas de compostos derivados da apomorfina; e o uso de compostos derivados da apomorfina nos métodos de tratamento de disfunções sexuais ou para intensificar a eficácia sa apomorfina para pacientes tratados com apomorfina são descritos. Os derivados da apomorfina podem ser ésteres, éteres, amidas, anidridos mistos, hemiacetais, glucuronatos, sulfatos ou fosfonatos. O derivado da apomorfina de preferência é a norapomorfina.
BR0109515-3A 2000-04-07 2001-03-29 Derivados da apomorfina e métodos para seu uso BR0109515A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19565000P 2000-04-07 2000-04-07
PCT/US2001/040393 WO2001076602A1 (en) 2000-04-07 2001-03-29 Apomorphine derivatives and methods for their use

Publications (1)

Publication Number Publication Date
BR0109515A true BR0109515A (pt) 2004-08-10

Family

ID=22722192

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109515-3A BR0109515A (pt) 2000-04-07 2001-03-29 Derivados da apomorfina e métodos para seu uso

Country Status (18)

Country Link
US (1) US6506765B2 (pt)
EP (1) EP1284735A4 (pt)
JP (1) JP2003532640A (pt)
KR (1) KR20030036157A (pt)
CN (1) CN1471395A (pt)
AU (1) AU2001255818A1 (pt)
BG (1) BG107217A (pt)
BR (1) BR0109515A (pt)
CA (1) CA2405419A1 (pt)
CZ (1) CZ20023637A3 (pt)
HU (1) HUP0301773A3 (pt)
IL (1) IL151614A0 (pt)
MX (1) MXPA02009904A (pt)
NO (1) NO20024806D0 (pt)
PL (1) PL361672A1 (pt)
SK (1) SK15772002A3 (pt)
WO (1) WO2001076602A1 (pt)
ZA (1) ZA200207489B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
KR20050008658A (ko) * 2002-03-19 2005-01-21 마이클 홀릭 아포모르핀의 글리코시드 및 오르토에스테르 글리코시드유도체들, 유사체들 및 그것의 용도
WO2004069167A2 (en) * 2003-01-31 2004-08-19 Nastech Pharmaceutical Company Inc. Method and compositions for treating male infertility
RU2364400C2 (ru) * 2003-04-14 2009-08-20 Вектура Лтд Фармацевтические композиции
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
ES3012497T3 (en) 2005-10-12 2025-04-09 Besins Healthcare Lu Sarl Improved testosterone gel and method of use
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
JP7320507B2 (ja) 2017-11-24 2023-08-03 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
EP3972971A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
CN113727712B (zh) 2019-05-21 2024-11-15 H.隆德贝克有限公司 用于治疗帕金森病的儿茶酚胺氨基甲酸酯前药
WO2020234274A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
JP7562562B2 (ja) 2019-05-21 2024-10-07 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
WO2023012736A1 (en) * 2021-08-05 2023-02-09 Zydus Lifesciences Limited Stable pharmaceutical compositions of apomorphine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
DE69434304T2 (de) 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
JP3310982B2 (ja) 1994-04-22 2002-08-05 ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド 男性の勃起機能不全を改善するための剤形及び方法
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
EP0914097B1 (en) 1996-03-12 2002-01-16 Alza Corporation Composition and dosage form comprising opioid antagonist
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US5925629A (en) * 1997-10-28 1999-07-20 Vivus, Incorporated Transurethral administration of androgenic agents for the treatment of erectile dysfunction
WO1999027905A1 (en) 1997-12-02 1999-06-10 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions for nasal administration
US5945117A (en) 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
AU4254799A (en) * 1998-06-22 2000-01-10 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
IT1299566B1 (it) * 1998-07-17 2000-03-16 Ifi Istituto Farmacoterapico I Cerotto transdermico e composizioni farmaceutiche comprendenti r (-)- norapropilapomorfina cloridrato e/o s (+) - norapropilapomorfina
US5994363A (en) 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
WO2000069416A1 (en) * 1999-05-13 2000-11-23 Unihart Corporation Pharmaceutical compositions comprising apocodeine and/or its derivatives

Also Published As

Publication number Publication date
PL361672A1 (en) 2004-10-04
CZ20023637A3 (cs) 2003-02-12
SK15772002A3 (sk) 2003-09-11
US6506765B2 (en) 2003-01-14
KR20030036157A (ko) 2003-05-09
BG107217A (bg) 2003-05-30
CN1471395A (zh) 2004-01-28
IL151614A0 (en) 2003-04-10
EP1284735A1 (en) 2003-02-26
MXPA02009904A (es) 2004-09-06
WO2001076602A1 (en) 2001-10-18
US20020002176A1 (en) 2002-01-03
EP1284735A4 (en) 2006-01-11
NO20024806D0 (no) 2002-10-04
CA2405419A1 (en) 2001-10-18
HUP0301773A2 (hu) 2003-09-29
AU2001255818A1 (en) 2001-10-23
JP2003532640A (ja) 2003-11-05
ZA200207489B (en) 2003-12-18
HUP0301773A3 (en) 2006-02-28

Similar Documents

Publication Publication Date Title
BR0109515A (pt) Derivados da apomorfina e métodos para seu uso
MY132705A (en) Novel compounds with analgesic effect
MY119181A (en) Aryl pyrimidine derivatives
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
BR0113643A (pt) Compostos de guanidinobenzamidas como agonistas de mc4-r e seus usos
BR0215240A (pt) Derivados de calcona e seu uso no tratamento de doenças
TR199901006T2 (xx) Heterosiklik t�revler.
MY119403A (en) Novel compounds with analgesic effect.
DE60042153D1 (de) Pharmauzetisch zusammensetzung nitratenquelle und ansäuerungsmitteln enthaltende zur behandlung von offenen wunden und verbrennungen
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
IL120317A0 (en) Otic antibacterial compositions
SE9900961D0 (sv) Novel compounds
EA200400689A1 (ru) Фармацевтические и косметические композиции, содержащие ароматические альдегиды, содержащие оксигруппу
AU3304400A (en) Tetrahydropyran derivatives and their use as therapeutic agents
BR0014355A (pt) Derivados de sapogenina e seu uso no tratamento de disfunção cognitiva
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
EP1074245A3 (en) Composition using mineral salts for therapeutic treatment
SE9802208D0 (sv) Novel compounds
PT1242410E (pt) Compostos novos
PT1109814E (pt) 5-heterociclil pirazol¬4,3-d|pirimidina-7-onas para o tratamento da disfuncao erectil masculina
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
SE9802209D0 (sv) Novel compounds
ES2163730T3 (es) Derivados espirocetales y su uso como agentes terapeuticos.
GEP20043231B (en) Resorcinol Composition
SE0000303D0 (sv) Novel compounds

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A., 7A. E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO DA RPI 2016 DE 25/08/2009.